Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
147
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Nadine Kutscha Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyCorrespondence[email protected]
View further author information
,
Emily Eva Holmesa Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyView further author information
,
Sandra Robrechta Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyView further author information
,
Gudrun Schülerb Praxis für Hämatologie und Onkologie Cottbus, Cottbus, GermanyView further author information
,
Ursula Vehling-Kaiserc BAG MVZ Dr. Vehling-Kaiser GmbH, Landshut, Landshut, GermanyView further author information
,
Thomas Deckerd Onkologie Ravensburg, Ravensburg, GermanyView further author information
,
Sigrun Müller-Hagene Onkologie und Palliativmedizin Hamburg, Praxis für Hämatologie, Hamburg, GermanyView further author information
,
Karin Heinischf Klinikum Lippe Standort Lemgo, Lemgo, GermanyView further author information
,
Sebastian Böttcherg Medizinische Klinik III, University Hospital of Rostock, Rostock, GermanyView further author information
,
Matthias Ritgenh Innere Medizin III, University Hospital Schleswig Holstein, Kiel, GermanyView further author information
,
Karl-Anton Kreuzeri Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, GermanyView further author information
,
Stephan Stilgenbauerj Division of CLL, Klinik für Innere Medizin III, University Hospital Ulm, Ulm, GermanyView further author information
,
Anna Maria Finka Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyView further author information
,
Kirsten Fischera Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyView further author information
,
Barbara Eichhorsta Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyView further author information
,
Michael Halleka Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, GermanyView further author information
&
Clemens-Martin Wendtnerk Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University (LMU), Munich, GermanyView further author information
 show all
Pages 478-482 | Received 18 Jun 2022, Accepted 03 Nov 2022, Published online: 24 Nov 2022

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Julio Bravo, Patricia Baltasar Tello, Esther González Garcia, Eduardo Ríos Herranz, Angel Ramirez Páyer, María José Terol Castera, Diana Champ, Angeles Medina Perez, Mercedes Gironella, Miguel Fernández Zarzoso, Rafael Forés, Julio Delgado, José A. Garcia-Marco, Alicia Rodríguez Fernández, Ana Muntañola Prat, Alexia Suárez Cabrera, José Manuel Puerta Puerta, Mercedes Rodríguez, Juana Clavel, Maria Victoria Dourdil Sahun, Christelle Ferra Coll, Ernesto Pérez Persona & Carmen Milagros Marrero Santos. (2023) Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study. Leukemia & Lymphoma 64:5, pages 913-926.
Read now
Tadeusz Robak. (2023) Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?. Leukemia & Lymphoma 64:5, pages 907-909.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.